Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
239.00
-1.08 (-0.45%)
At close: Aug 26, 2026, 4:00 PM EDT
238.18
-0.82 (-0.34%)
After-hours: Aug 26, 2026, 7:47 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 28 analysts polled by S&P Global, Alnylam Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $370.2. The average 1-year stock price forecast is 54.90% higher than the current stock price, while the lowest is $230 (-3.77%) and the highest is $536 (+124.27%).
Price Target: $370.2 (+54.90%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 15 | 14 | 14 | 15 |
| Buy | 6 | 6 | 7 | 7 | 8 | 7 |
| Hold | 8 | 8 | 8 | 8 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 28 | 28 | 30 | 29 | 28 | 28 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bernstein | Bernstein | Buy Maintains $376 | Buy | Maintains | $376 | +57.32% | Aug 24, 2026 |
Unknown Analyst BMO Capital No rating | BMO Capital | Buy Initiates $318 | Buy | Initiates | $318 | +33.05% | Aug 18, 2026 |
Unknown Analyst Wells Fargo No rating | Wells Fargo | Hold Reiterates $316 → $256 | Hold | Reiterates | $316 → $256 | +7.11% | Aug 14, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $318 | Buy | Maintains | $318 | +33.05% | Aug 13, 2026 |
| Evercore ISI | Evercore ISI | Buy Maintains $400 → $325 | Buy | Maintains | $400 → $325 | +36.07% | Aug 5, 2026 |
Financial Forecast
Revenue This Year
5.49B
from 3.71B
Increased by 47.85%
Revenue Next Year
6.94B
from 5.49B
Increased by 26.40%
EPS This Year
8.92
from 5.08
Increased by 75.50%
EPS Next Year
12.59
from 8.92
Increased by 41.18%
EPS and Forward PE are based on non-GAAP adjusted numbers.